

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: **0 610 553 A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93117267.0

(51) Int. Cl.⁵: **C07D 215/48, C07D 215/18,
C07D 401/12, C07D 209/08,
A61K 31/47, A61K 31/40**

(22) Date of filing: 25.10.93

A request for correction of the description has been filed pursuant to Rule 88 EPC. A decision on the request will be taken during the proceedings before the Examining Division (Guidelines for Examination in the EPO, A-V, 2.2).

(30) Priority: 17.11.92 US 977340

(43) Date of publication of application:
17.08.94 Bulletin 94/33

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

(71) Applicant: **E.R. SQUIBB & SONS, INC.**
P.O.Box 4000
Princeton New Jersey 08543-4000 (US)


(72) Inventor: Atwal, Karnal
92 Valley View Way
Newtown, PA 18940 (US)
Inventor: Ferrara, Francis N.
1745 Arrowbrook Drive
Martinsville, NJ 08836 (US)

(74) Representative: Josif, Albert, Dr.-Ing. et al
Baaderstrasse 3
D-80469 München (DE)

(54) Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline.

(57) Novel compounds having potassium channel activating activity and useful, for example, as antiischemic agents are disclosed. These compounds have the general formula

I



wherein A is



or a single bond to complete an indoline nucleus; X is -O-, -S- or -NCN; and the R groups are as defined herein

EP 0 610 553 A1

In accordance with the present invention novel compounds having potassium channel activating activity and useful, for example, as antiischemic agents are disclosed. These compounds have the general formula

I

5

10

15

and pharmaceutically acceptable salts thereof wherein
A is

20



25 or a single bond to complete an indoline nucleus;

X is -O-, -S- or -NCN;

R₁ is aryl, arylalkyl, heterocyclo or (heterocyclo)alkyl;

R₂ is hydrogen, alkyl or arylalkyl;

30 or R₁ and R₂ taken together form a 5- to 7-membered saturated or unsaturated ring, which may further include an aryl group fused to 2 carbon atoms of such 5- to 7-membered ring;

R₃, R₄, R₇ and R₈ are each independently hydrogen, alkyl or arylalkyl; or R₃ and R₄, or independently R₇ and R₈, taken together with the carbon atoms to which they are attached form a 5- to 7-membered carbocyclic ring, with the proviso that when A is


35




40 and R₇ and R₈ are other than hydrogen, then R₃ and R₄ are hydrogen, or when R₇ and R₈ are hydrogen then, R₃ and R₄ are other than hydrogen;

R₅ is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, (cycloalkyl)alkyl, -CN, -NO₂, -COR, -COOR, -CONHR, -CON(R)₂, -CF₃, S-alkyl, -SOalkyl, -SO₂alkyl,

45



50



55

halogen, amino, substituted amino, -O-alkyl, -OCF₃, -OCH₂CF₃, -OCOalkyl, -OCONRalkyl, -NRCOalkyl, NRCOOalkyl or -NRCON(R)₂ wherein R is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl or haloalkyl;

R₆ is hydrogen, alkyl, halo, -OH, -O-alkyl, amino, substituted amino, -O-alkyl, -OCOalkyl, -OCONRalkyl, -NRCOalkyl, -NRCOOalkyl or -NRCON(R)₂; and
n is an integer of 1, 2 or 3

This invention relates to the novel compounds of formula I which are useful as antiischemic agents

The term "alkyl" used in defining various symbols refers to straight or branched chain saturated hydrocarbon radicals having up to eight carbons, preferably from one to five carbons. Similarly, the terms
"alkoxy" and "alkylthio" refer to such alkyl groups attached to an oxygen or sulfur



The term "alkenyl" refers to straight or branched chain hydrocarbon radicals having from two to eight carbons and at least one double bond, preferably three to five carbons. The term "alkynyl" refers to straight or branched chain hydrocarbon radicals having from two to eight carbons and at least one triple bond, preferably three to five carbons

The term "cycloalkyl" refers to saturated carbocyclic rings of 3 to 7 carbon atoms with cyclopropyl, cyclopentyl and cyclohexyl being most preferred

The term "halo" or "halogen" refers to chlorine, bromine, iodine or fluorine

The term "halo substituted alkyl" refers to such alkyl groups described above in which one or more hydrogens have been replaced by chloro, bromo, iodo or fluoro groups such as chloromethyl, bromomethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trichloroethyl or 2,2,2-trifluoroethyl. Trifluoromethyl is preferred

The term "aryl" refers to phenyl, 1-naphthyl, 2-naphthyl or mono substituted phenyl, 1-naphthyl, 2-naphthyl wherein said substituent is alkyl of 1 to 4 carbons, (amino)alkyl, (substituted amino)alkyl, alkylthio of 1 to 4 carbons, alkoxy of 1 to 4 carbons, halo, nitro, cyano, hydroxy, amino, -NH-alkyl wherein alkyl is of 1 to 4 carbons, -N(alkyl)₂ wherein alkyl is of 1 to 4 carbons, -CF₃, -O(haloalkyl).



(wherein R₉ is hydrogen, alkyl of 1 to 4 carbons, alkoxy of 1 to 4 carbons, alkylthio of 1 to 4 carbons, halo, hydroxy or -CF₃), -O-CH₂-cycloalkyl, -S-CH₂-cycloalkyl, or -alkyl(COOR₁₀) (wherein R₁₀ is hydrogen or alkyl), and di-substituted phenyl, 1-naphthyl, 2-naphthyl wherein said substituents are methyl, methoxy, methylthio, halo, -CF₃, nitro, amino, -OCHF₂, or -alkyl(COOR₁₀).

Preferred aryl groups include unsubstituted phenyl and monosubstituted phenyl wherein the substituents are nitro, halo, -CF₃, alkyl, cyano, methoxy, or -alkyl(COOR₁₀).

The term "heterocyclo" refers to fully saturated or unsaturated rings of 5 or 6 atoms containing one or two O and S atoms and/or one to four N atoms provided that the total number of hetero atoms in the ring is 4 or less. The hetero ring is attached by way of an available atom. Preferred monocyclic heterocyclic groups include 2- and 3-thienyl, 2- and 3-furyl, 2-, 3- and 4-pyridyl, and imidazolyl. The term heterocyclo also includes bicyclic rings wherein the five or six membered ring containing O, S and N atoms as defined above is fused to a benzene ring and the bicyclic ring is attached by way of an available carbon atom. Preferred bicyclic hetero groups include 4, 5, 6, or 7-indolyl, 4, 5, 6, or 7-isindolyl, 5, 6, 7 or 8-quinoliny, 5, 6, 7 or 8-isoquinoliny, 4, 5, 6, or 7-benzothiazolyl, 4, 5, 6 or 7-benzoxazolyl, 4, 5, 6 or 7-benzimidazolyl, 4, 5, 6 or 7-benzodiazolyl, and 4, 5, 6 or 7-benzofuranzanyl


The term heterocyclo also includes such monocyclic and bicyclic rings wherein an available carbon atom is substituted with a lower alkyl of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, halo, nitro, keto, cyano, hydroxy, amino, -NH-alkyl wherein alkyl is of 1 to 4 carbons, -N(alkyl)₂ wherein alkyl is of 1 to 4 carbons, -CF₃, or -OCHF₂; or such monocyclic and bicyclic rings wherein two or three available carbons are substituted with methyl, methoxy, methylthio, halo, -CF₃, nitro, hydroxy, amino

or -OCHF₂

The term "substituted amino" refers to a group of the formula -NZ₁Z₂ wherein Z₁ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl and Z₂ is alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl or Z₁ and Z₂ taken together with the nitrogen atom to which they are attached are 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiomorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, or 4-diarylalkyl-1-piperazinyl, each of which may be optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy


The compounds of formula I wherein X is oxygen can be prepared by treatment of a compound of the formula

II



with a compound of the formula

III



in an organic solvent, such as dimethylformamide, tetrahydrofuran, acetonitrile or dichloromethane.

Compounds of formula I wherein R₂ is hydrogen and X is oxygen or sulfur can also be prepared by reacting a compound of formula III with an isocyanate or isothiocyanate of the formula




where X is oxygen or sulfur.

Compounds of formula I wherein X is NCN can be prepared by treatment of compounds of formula I wherein X is sulfur with cyanamide in the presence of dicyclohexyl cardodiimide or 1-(3-dimethylaminopropyl)-2-ethylcarbodiimide hydrochloride

Compounds of formula I wherein X is NCN can also be prepared by treatment of an intermediate of formula

V



with a compound of formula III

Compounds of formula I wherein X is NCN can also be prepared by first treating compounds of formula III with diphenylcyanocarbonimidate in the presence of an organic base such as pyridine or triethylamine, followed by reaction with an amine of formula

VI



5


optionally in the presence of trimethylaluminum.

Compounds of formula II can be prepared, for example, by treatment of a compound of the formula VI with 4-nitrophenylchloroformate

10 The compounds of formula III where A is a single bond. R_5 is -CN and R_3 and R_4 are each hydrogen and R_7 and R_8 are as defined, can be prepared according to Scheme 1

Scheme 1

15




55

Benzene or a substituted derivative thereof is alkylated with an α,β -unsaturated ketone in the presence of a Lewis acid (aluminum chloride, tin chloride etc.) to provide a compound of formula VII which upon oxidation with, for example sodium hypobromide, gives the acid of formula VIII. The acid is converted to its chloride

by treatment with phosphorus oxychloride or thionyl chloride, which on treatment with a Lewis acid gives an indanone of formula IX. The aromatic ring is nitrated with fuming nitric acid to give a compound of formula X which upon catalytic hydrogenation gives the amino compound of formula XI. The amino compound is converted to the bromide XII via its diazonium salt, prepared by treatment with sodium nitrite and hydrobromic acid. The ketone XII is converted to its oxime XIII under standard conditions (hydroxylamine hydrochloride and sodium acetate). The oxime XIII is subjected to reductive Beckman rearrangement (diisobutylaluminum hydride in an organic solvent such as tetrahydrofuran, diethyl ether) via its tosylate XIV, prepared from XIII by treatment with tosyl chloride in the presence of an organic base such as pyridine or triethyl amine. The bromide in the resulting product XV can be replaced with other groups such as nitrile (e.g., XVI), trifluoromethyl, O-alkyl, S-alkyl, alkenyl, alkynyl etc. by methods described in the literature.

Compounds of formula III wherein A is $-\text{CH}_2-$, R_5 is $-\text{CN}$ and R_3 and R_4 are as defined, can be prepared according to Scheme 2


Scheme 2



The indanone XVII is alkylated with an alkyl halide and a base such as potassium *tert*-butoxide to give compound XVIII which upon nitration (fuming nitric acid) provides XIX. The nitro group in XIX is changed to the bromide XXI via the same reaction sequence as described for compounds X to XII in Scheme 1. The reductive Beckman rearrangement of oxime XXII proceeded under standard conditions (diisobutylaluminum hydride in tetrahydrofuran) to give bromotetrahydroquinoline XXIII in good overall yield. The bromine in XXIII can be changed to other groups (e.g., CN, CF_3 , O-alkyl, S-alkyl etc.) under standard conditions, such as those shown for the preparation of compound XXIV.

Compounds of formula III wherein A is a single bond, R_5 is $-\text{CN}$ and R_3 and R_4 are as defined, can be prepared according to Scheme 3

Scheme 3



Bromination of indole XXV with N-bromosuccinimide gives the dibromide of formula XXVI which upon acid hydrolysis (sulfuric acid, hydrochloric acid in an organic solvent such as dioxane) provides the amide of formula XXVII. The nitrogen in XXVII is protected (acetic anhydride and an organic base such as pyridine or methyl amine) and the resulting acetamide XXVIII is alkylated with an alkyl halide and a base such as sodium hydride to give XXIX. The acetate in XXIX is removed by treatment with an aqueous base such as sodium hydroxide and the amide XXX is reduced with a reducing agent such as sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al). The resulting product XXXI is protected (acetic anhydride and an organic base such as pyridine or triethyl amine) as an acetamide XXXII and the bromine is changed to an appropriate group (e.g., CN, CF₃, O-alkyl, S-alkyl etc.) under standard conditions. The acetamide protecting group is then removed by treatment with aqueous acid (hydrochloric acid, sulfuric acid in an organic solvent such as dioxane) to provide a compound of formula XXXIV.

Compounds of formula IV are commercially available.


Compounds of the formula V can be prepared by treatment of compounds of the formula VI with diphenylcyanocarbonimide.

Compounds of formula VI are commercially available.

The compounds of the present invention can have asymmetric centers at carbons 2-4 of tetrahydroquinoline or carbons 2, 3 of indoline rings. Also, any one of the R's can have an asymmetric carbon. Consequently, compounds of formula I can exist in diastereomeric forms or in mixtures thereof. The above described process can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric products are prepared, they can be separated by conventional chromatographic or fractional crystallization methods.


The compounds of the present invention wherein R₂ is hydrogen can exist as a mixture of tautomers represented by the following structures. The tautomeric products are obtained in relative amounts that differ from compound to compound. All forms are included in the scope of formula

I



such as compounds of formula

I'



Preferred compounds are those wherein A is



or a single bond;

R₁ is aryl, arylalkyl, heterocyclo or (heterocyclo)alkyl;

R₂ is hydrogen or alkyl;

R₃ and R₄ are independently hydrogen or alkyl;

R₅ is an electron withdrawing group;


R₆ is hydrogen, alkyl or O-alkyl;

R₇ and R₈ are independently alkyl; and

X is O or NCN.

Most preferred are those compounds wherein

A is



5

or a single bond;

R₁ is phenyl, phenylmethyl, substituted phenyl, substituted phenylmethyl or pyridyl;

R₂ is hydrogen;

R₃ and R₄ are independently hydrogen or methyl;

10

R₅ is -CN or -NO₂;

R₆ is hydrogen;

R₇ and R₈ are independently hydrogen or methyl; and

X is O or NCN

The compounds of formula I and the pharmaceutically acceptable salts act as potassium channel
15 activators. Thus, compounds of the present invention are useful cardiovascular agents, e.g. as anti-
arrhythmic agents and antiischemic agents.

Compounds of formula I are particularly useful as antiischemic agents since they have been found to
possess little or no vasodilatory activity. Thus, compounds of formula I are useful for the treatment of
ischemic conditions, e.g. myocardial ischemia, cerebral ischemia, lower limb ischemia and the like. The
20 selectivity, i.e., antiischemic activity with little or no vasodilatory activity, means that in the treatment of, for
example, ischemic heart, these compounds are less likely to cause coronary steal, profound hypotension
and coronary underperfusion. By little or no vasodilation activity is meant that these compounds have IC₅₀ -
(rat aorta) values greater than that of the potassium channel activator, cromakalim. The "selective"
antiischemic agents typically are those having IC₅₀ (rat aorta) values >10 times that of cromakalim (i.e.
25 have 1/10 the vasodilatory action) and preferably those having IC₅₀ values >50 times that of cromakalim.

Thus, for example, by the administration of a composition containing one (or a combination) of the
compounds of this invention, ischemic conditions of a mammalian (e.g., human) host are reduced. A single
dose, or preferably two to four divided daily doses, provided on a basis of about 0.001 to 100 mg per
kilogram of body weight per day, preferably from about 0.1 to about 25 mg per kilogram per day, is
30 appropriate to reduce ischemic conditions. The substance is preferably administered orally, but parenteral
routes, such as the subcutaneous, intramuscular, or intravenous routes or any other convenient delivery
system, such as inhalation or intranasal solutions or transdermal patches, can also be employed. The above
doses are also suitable for the other cardiovascular and non-cardiovascular uses.

As a result of the potassium channel activating activity of compounds of this invention, these
35 compounds are also useful in the treatment of cardiovascular disorders. For example, compounds of the
present invention are useful as therapy for congestive heart failure, as anti-anginal agents, as anti-fibrillatory
agents, and in limiting myocardial infarction.

Compounds of the present invention are additionally expected to be useful in the treatment of central
nervous system disorders (e.g., Parkinsonism, as anti-tremor agents, epilepsy).

40 The compounds of this invention can also be formulated in combination with a diuretic such as,
chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylch-
lothiazide, trichloromethiazide, polythiazide or benzthiazide as well as ethacrynic acid, tricyclic, chlor-
thalidone, furosemide, musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such
compounds, angiotensin converting enzyme inhibitors such as captopril, zofenopril, fosinopril, enalapril,
45 ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril, and salts of such compounds, throm-
bolytic agents such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase,
prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC, Eminase, Beecham
Laboratories), or calcium channel blocking agents such as nifedipine or diltiazem. Such combination
products if formulated as a fixed dose employ the compounds of this invention within the dose range
50 described above and the other pharmaceutically active agent within its approved dose range.

The compounds of formula I, and combinations thereof, can be formulated, as described above, in
compositions such as tablets, capsules or elixirs for oral administration, in sterile solutions or suspensions
for parenteral administration, and may also be administered via transdermal patch or nasal inhalation
solutions. About 10 to 500 milligrams of a compound of formula I is compounded with physiologically
55 acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc. in a unit dosage form as
called for by accepted pharmaceutical practice. The amount of active substance in these compositions or
preparations is such that a suitable dosage in the range indicated is obtained.

Specific embodiments of the present invention are described hereinafter in the following examples

Example 17-Cyano-3,4-dihydro-4,4-dimethyl-N-phenyl-1(2H)-quinoline-carboxamide5 A 4-Methyl-4-phenyl-2-pentanone

To a slurry of AlCl_3 (40.0 g, 0.3 mole) in benzene (90 mL) maintained at 10°C under argon was added dropwise mesityl oxide (0.2 mole, 19.63 g). Upon completion of the addition the reaction was stirred at room temperature for 15 hours. The reaction mixture was poured onto ice/10% HCl (350 g). The organic layer
 10 was separated and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organics were washed with distilled H_2O , saturated NaHCO_3 solution, saturated NaCl solution and dried over Na_2SO_4 . The solvent was recovered under vacuum and the crude product (31.6 g) was vacuum distilled (b.p. = 107°C @ 3.0 mmHg) to obtain 24.5 g (69%) of the title A compound as a colorless oil. MS: (M+H)⁺ @ 177

15 B 3-Methyl-3-phenylbutanoic acid

To a solution of NaOH (47.2 g, 1.18 mole) in ice/ H_2O (270 g) maintained at $4-5^\circ\text{C}$ was added Br_2 (68.7 g, 0.43 mole) followed by 4-methyl-4-phenyl-2-pentanone (23.7 g, 0.135 mole). The reaction was stirred for
 20 18 hours at room temperature. The crude reaction mixture was extracted with CCl_4 (discarded), acidified to pH 1-2 with concentrated HCl solution and extracted with ethyl acetate. The combined organics were washed with saturated NaCl solution, dried over Na_2SO_4 and evaporated *in vacuo* to obtain 22.5 g of the title B compound as a off-white solid. This was used in the next step without further purification. MS: (M+ NH_4)⁺ @ 196

25 C 3,3-Dimethyl-1-indanone

To a solution of 3-methyl-3-phenyl butanoic acid (17.1 g, 95.5 mmoles) in benzene (70 mL) was added PCl_5 (23.0 g, 0.11 mole, 1.15 eq) portionwise with cooling. Upon completion of the addition, the reaction
 30 mixture was refluxed for 30 minutes and cooled to room temperature. Aluminum chloride (13.1 g, 98.3 mmoles) was added in increments and the reaction was heated at reflux for 30 minutes. The reaction mixture was poured onto ice; the oily layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organics were washed with 5% HCl solution, saturated NaHCO_3 solution, saturated NaCl solution and dried over MgSO_4 . The solvent was evaporated *in vacuo* and the crude product (14.3 g)
 35 was vacuum distilled (b.p. = 103°C @ 2.3 mmHg) to obtain 9.98 g of the title C compound as a colorless oil. MS: (M+H)⁺ @ 161

D 1,1-Dimethyl-5-nitro-3-indanone

A mixture of nitric acid (90% fuming, 35 mL) and urea (0.17 g) was cooled to -10°C and purged with air for 20 minutes; 3,3-dimethyl-1-indanone (8.68 g, 54.2 mmoles) was added and the reaction was stirred for
 40 two hours at -10°C to 5°C . The reaction mixture was poured into ice/ H_2O and extracted with ethyl acetate. The combined extracts were washed with distilled H_2O , saturated NaHCO_3 solution, saturated NaCl solution, and dried over MgSO_4 . The solvent was recovered under vacuum to obtain 10.0 g of a yellow solid. The
 45 crude product was recrystallized from methanol in two crops to obtain 8.08g (71%) of the title D compound as yellow needles. MS: M⁺ @ 205

E 5-Amino-1,1-dimethyl-indan-3-one

A solution of the title D compound (6.5 g, 31.7 mmoles) in methanol (150 mL) containing 5% Pd/C (0.75 g) was stirred under H_2 at 15 psi for four hours. The catalyst was filtered and the methanol was recovered
 50 under vacuum to obtain 5.72 g of the title E compound as a green solid. The reaction product was used in the next step without further purification.

55 F 5-Bromo-1,1-dimethylindan-3-one

To a solution of the title E compound (6.02 g, 34.4 mmole) in a mixture of 48% aqueous HBr solution (9.7 mL) and ethanol (30 mL) cooled to 0°C was added NaNO_2 until a positive starch-iodide test was

obtained. The cold diazonium salt solution was added via pipette to a mixture of CuBr (5.42 g, 18.9 mmole) and 48% aqueous HBr solution at 95 °C. The reaction mixture was heated at reflux for 15 minutes, cooled to room temperature and partitioned between ethyl acetate and distilled H₂O. The organic phase was washed with saturated NaHCO₃ solution, saturated NaCl solution, dried over MgSO₄ and evaporated *in vacuo* to obtain 7.33 g of an orange solid. The crude product was chromatographed on silica eluting with hexane/ethyl acetate (4:1) to obtain 6.52 g of the title F compound as a yellow solid; m.p. 117-118 °C.

G 5-Bromo-1,1-dimethylindan-3-one oxime

A solution of the title F compound (6.52 g, 27.3 mmole) in ethanol (130 mL) containing NH₂OH·HCl (3.79 g, 54.5 mmole) and sodium acetate (4.03 g, 49.1 mmole) was heated at reflux for 2.5 hours. The solvent was recovered under vacuum and the residue was partitioned between ethyl acetate and distilled H₂O. The organic phase was washed with saturated NaCl, dried over MgSO₄, and evaporated *in vacuo* to obtain 6.94 g of the title G compound as a yellow solid. The product was used in the next step without further purification; m.p. 115-117 °C.

H. 5-Bromo-1,1-dimethylindan-3-one oxime tosylate

To a solution of the title G compound (5.30 g, 20.9 mmole) in pyridine (50 mL) cooled to 0 °C was added p-toluenesulfonyl chloride (4.77 g, 25.0 mmole). The solution was warmed to room temperature and stirred for 18 hours. The reaction mixture was diluted with ethyl acetate and washed with cold 10% aqueous HCl solution, distilled H₂O, saturated NaHCO₃ solution, saturated NaCl solution and dried over MgSO₄. The solvent was recovered under vacuum to obtain 8.74 g of the title H compound as an orange gum which slowly crystallized on standing. The compound was used in the next step without further purification.

I 7-Bromo-3,4-dihydro-4,4-dimethyl-1(2H)-quinoline

To a solution of the title H compound (7.74 g, 19.0 mmole) in methylene chloride (95.0 mL) cooled to -78 °C was added diisobutylaluminum hydride (1M solution in hexane, 95.0 mL). The reaction mixture was stirred 0.5 hours at -78 °C followed by five hours at 0 °C. The crude product solution was diluted with methylene chloride (200 mL) and quenched while stirring vigorously by the addition of sodium fluoride (16.0 g) and distilled H₂O (5.20 g). The solids were filtered and the filtrate was dried over MgSO₄ and evaporated *in vacuo* to obtain 4.80 g of an orange gum. The crude product was chromatographed on silica eluting with 15% ethyl acetate in hexane to obtain 2.23 g of the title I compound as a light yellow oil.

J 7-Cyano-3,4-dihydro-4,4-dimethyl-1(2H)-quinoline

A mixture of the title I compound (2.24 g, 9.33 mmole), CuCN (1.67 g, 18.7 mmole) and 1-methyl-2-pyrrolidinone (22.5 mL) was heated at 185-190 °C for 3.25 hours. The reaction mixture was diluted with ethyl acetate and filtered. The volatiles were recovered under vacuum and the residue was chromatographed on silica eluting with 15% ethyl acetate in hexane to obtain 0.92 g (53%) of the desired title J product as a light yellow oil.

K 7-Cyano-3,4-dihydro-4,4-dimethyl-N-phenyl-1(2H)-quinolinecarboxamide

A solution of the title J compound (0.20 g, 1.07 mmole), phenyl isocyanate (0.13 g, 1.07 mmole) and 4-dimethylaminopyridine (50 mg) in acetonitrile (4.5 mL) was heated under argon at reflux for one hour. The solvent was recovered under vacuum and the residue was triturated with isopropyl ether to afford 0.27 g of the title compound as an off-white solid; m.p. 174-175 °C.

Analysis calculated for C ₁₉ H ₁₉ N ₃ O:			
	C, 74.73;	H, 6.27;	N, 13.76;
Found:	C, 74.46;	H, 6.26;	N, 13.77

Example 27-Cyano-3,4-dihydro-4,4-dimethyl-N-(phenylmethyl)-1(2H)-quinolinecarboxamide

5 A solution of the title J compound from Example 1 (0.20 g, 1.07 mmole), benzyl isocyanate (0.14 g, 1.07 mmole) and 4-dimethylaminopyridine (50 mg) in acetonitrile (4.5 mL) was heated under argon at reflux for one hour. The solvent was recovered under vacuum and the crude product was chromatographed on silica eluting with hexane/ethyl acetate (7:3) to afford 0.30 g of the title compound as a white solid; m.p. 114-115°C.

Analysis calculated for $C_{20}H_{21}N_3O$:			
Found:	C, 75.21; C, 75.05;	H, 6.63; H, 6.63;	N, 13.16; N, 12.98.

Example 3N-(3-chlorophenyl)-7-cyano-3,4-dihydro-4,4-dimethyl-1(2H)-quinolinecarboxamide

20 A solution of 7-cyano-3,4-dihydro-4,4-dimethyl-1(2H)-quinoline (0.16 g, 0.86 mmole, compound of example 1, part J) and 3-chlorophenyl-isocyanate (0.14 g, 0.90 mmole) in acetonitrile (3.75 mL) containing N,N-dimethylaminopyridine (30 mg) was heated at reflux under argon for three hours. The solvent was recovered under vacuum to obtain 0.38 g of crude product as a yellow gum. The crude material was purified by chromatography on silica eluting with hexane/ethyl acetate (3:1) to obtain 270 mg of a white solid. The chromatography isolate was further purified by crystallization from isopropanol to obtain the title compound (190 mg, 65%) as a white solid; mp. 150-152°C. MS: (M+H)⁺ @ 340.

Analysis calculated for $C_{19}H_{18}ClN_3O \cdot 0.22 H_2O$:				
Found:	C, 66.38; C, 66.55;	H, 5.41; H, 5.37;	N, 12.22; N, 12.05;	Cl, 10.31; Cl, 10.50.

Example 47-Cyano-1,2,3,4-tetrahydro-3,3-dimethyl-N-phenyl-1-quinolineamide40 A 3,3-Dimethylindan-1-one

To a solution of 1-indanone (30 g, 0.23 mole) in dry benzene (350 mL) at room temperature under argon was added solid potassium(*tert*)-butoxide (95%, 68 g, 0.58 mole). Methyl iodide (65.3 g, 0.46 mole) was added to the deep purple slurry with cooling over one hour. The reaction mixture was heated at reflux for two hours and poured over 400 g of ice containing concentrated HCl solution (90 mL). Diethyl ether was added and the organic phase was separated. The aqueous phase was extracted with diethyl ether. The combined organic layers were washed with 5% sodium carbonate solution followed by saturated sodium chloride solution. The extracts were dried over magnesium sulfate and evaporated *in vacuo* to obtain 40 g of a dark brown oil. The oil was dissolved in ethyl acetate, treated with activated charcoal, and filtered through a pad of celite and silica gel. The filtrate was concentrated to obtain 34.6 g of an orange solid. The partially purified material was triturated with cold pentane to afford 24.3 g (66%) of the title compound as a yellow solid. MS: (M+H)⁺ @ 161.

55 B 3,3-Dimethyl-6-nitroindan-1-one

A solution of urea (0.40 g) in nitric acid (90% fuming, 80 mL) was purged with air for twenty minutes, then cooled to -5°C. To this solution was added the title A compound (20.0 g, 0.12 mole) in portions while maintaining the reaction temperature <5°C. The reaction mixture was stirred at -5 to +5°C for two hours.

and poured over ice. The aqueous mixture was extracted with ethyl acetate. The extracts were washed with saturated sodium bicarbonate solution, saturated sodium chloride solution, and dried over magnesium sulfate. The solvent was recovered under vacuum to obtain 27.3 g of an orange solid. The crude material was crystallized from methanol to obtain 18.0 g (73%) of the title compound as a yellow crystalline solid.

5 MS: (M + NH₄)⁺ @ 223

C. 6-Amino-3,3-dimethylindan-1-one

To a solution of the title B compound (10.0 g, 48.7 mmole) in ethanol (100 mL) was added stannous chloride dihydrate (54.9 g, 0.24 mole). The mixture was heated at 75 °C for one hour. The reaction mixture was poured over ice and neutralized by the addition of solid sodium bicarbonate. The pH was adjusted to 11-12 with 10N sodium hydroxide solution and the reaction mass was extracted with ethyl acetate. The extracts were washed with saturated sodium chloride solution, dried over magnesium sulfate and evaporated *in vacuo* to obtain 8.19 g (96%) of the title compound as a tan solid. The compound was used in the next step without further purification.

D. 6-Bromo-3,3-dimethylindan-1-one

To a solution of title C compound (21.48 g, 71.2 mmole) in ethanol (65 mL) cooled to 0 °C was added 48% aqueous HBr (20 mL) followed by sodium nitrite solution (4.91 g dissolved in 8.8 mL of H₂O) until a positive starch/iodide test result was obtained. The cold diazonium salt solution was added directly via pipette to a refluxing mixture of CuBr (11.23 g, 78.3 mmole) and 48% aqueous HBr (20 mL). The reaction mixture was refluxed an additional 15 minutes upon completion of the addition, cooled to room temperature, and partitioned between ethyl acetate and 2N HCl. The organic phase was washed with 2N HCl, saturated sodium bicarbonate solution, saturated sodium chloride solution, and dried over magnesium sulfate. The solvent was recovered under vacuum to obtain 15.55 g of an orange solid. The product was purified by trituration with cold pentane to obtain 13.17 g (77%) of the title compound as a pale yellow solid. MS: (M + H)⁺ @ 239.

30 E. 6-Bromo-3,3-dimethylindan-1-one oxime

A mixture of title D compound (11.64 g, 48.67 mmole), hydroxylamine hydrochloride (6.76 g, 97.3 mmole) and sodium acetate (7.19 g, 87.6 mmole) in ethanol (230 mL) was heated at reflux for 36 hours. The ethanol was recovered under vacuum and the residue was partitioned between distilled H₂O and ethyl acetate. The organic fraction was washed with 1N NaOH solution, saturated sodium chloride solution, dried over magnesium sulfate and evaporated *in vacuo* to obtain 12.27 g (99%) of an off-white solid as a 29:1 mixture of syn and anti oximes. The isomer mixture was chromatographed on silica eluting with 7.5% ethyl acetate in hexane to afford 8.94 g of the title product (syn isomer) as a white solid. MS: (M + H)⁺ @ 254.

40 F. 7-Bromo-3,3-dimethyl-1,2,3,4-tetrahydro-1-quinoline

To a solution of title E compound (5.0 g, 19.7 mmole) in methylene chloride (200 mL) at 0 °C was added diisobutylaluminum hydride solution (1M in hexane, 5 eq., 147 mL) dropwise with stirring. The reaction mixture was stirred at 0 °C for 18 hours after which time it was diluted with methylene chloride (400 mL) and quenched by the addition of sodium fluoride (24.8 g) followed by distilled H₂O (8 mL). The solids were filtered and the filtrate was evaporated under vacuum to obtain an off-white solid (5.0 g). The crude material was chromatographed on silica eluting with hexane/ethyl acetate (9:1) to obtain the title compound (2.26 g, 48%) as a white solid.

50 G. 7-Cyano-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline

A solution of title F compound (3.75 g, 15.6 mmole) in 1-methyl-2-pyrrolidinone (40 mL) containing copper(I) cyanide (2.80 g, 31.2 mmole) was heated at 180 °C for two hours. The reaction mixture was cooled to room temperature, diluted with a large volume of diethyl ether, and filtered. The filtrate was washed with 1N sodium hydroxide solution followed by saturated sodium chloride solution and dried over sodium sulfate. The solvent was evaporated *in vacuo* to obtain 2.89 g of a brown solid. The crude product was chromatographed on silica eluting with 15% ethyl acetate in hexane to obtain the title G product (1.80 g, 62%) as a yellow solid. MS: (M + H)⁺ @ 187.

H 7-Cyano-1,2,3,4-tetrahydro-3,3-dimethyl-N-phenyl-1-quinolinamide

A solution of title G compound (0.275 g, 1.48 mmoles) and phenylisocyanate (0.18 g, 1.49 mmoles) in acetonitrile (6 mL) containing a catalytic amount of N,N-dimethylaminopyridine was heated at reflux under argon for one hour. The solvent was evaporated *in vacuo* and the residue thus obtained was triturated with isopropyl ether to afford the title compound 0.44 g (97%) as a colorless solid; m.p. 170-171 °C. MS: (M+H)⁺ @ 306.

Analysis calculated for C ₁₉ H ₁₉ N ₃ O:			
	C, 74.73;	H, 6.27;	N, 13.76;
Found:	C, 74.62;	H, 6.22;	N, 13.74.

Example 57-Cyano-1,2,3,4-tetrahydro-3,3-dimethyl-N-(phenylmethyl)-1-quinolineamide

A solution of 7-cyano-1,2,3,4-tetrahydro-3,3-dimethyl-quinoline (0.30 g, 1.61 mmoles, compound of example 1, part G) and benzylisocyanate (0.18 g, 1.49 mmoles) in acetonitrile (6.75 mL) containing a catalytic amount of N,N-dimethylaminopyridine was heated at reflux under argon for twelve hours. The solvent was evaporated *in vacuo* and the residue was triturated with isopropyl ether to afford the title compound (0.37 g, 72%) as a colorless solid; m.p. 162-163 °C. MS: (M+H)⁺ @ 320.

Analysis calculated for C ₂₀ H ₂₁ N ₃ O•0.12H ₂ O:			
	C, 74.71;	H, 6.66;	N, 13.07;
Found:	C, 74.80;	H, 6.58;	N, 12.98.

Example 67-Cyano-1,2,3,4-tetrahydro-4,4-dimethyl-N-(3-pyridinyl)-1-quinolinecarboxamide

The title compound was prepared from 7-cyano-3,4-dihydro-4,4-dimethyl-1(2H)-quinoline (compound of example 1, part J) and 3-pyridylisocyanate by the same method as described in example 1, part K. The product was obtained as a colorless powder; m.p. 183-185 °C.

Analysis calculated for C ₁₈ H ₁₈ N ₄ O•0.1ethyl acetate•0.19H ₂ O:			
	C, 69.37;	H, 6.07;	N, 17.59;
Found:	C, 69.35;	H, 5.94;	N, 17.32.

Example 77-Cyano-1,2,3,4-tetrahydro-3,3-dimethyl-N-(3-pyridinyl)-1-quinolinamide

A solution of title 4G compound (0.25g, 1.34 mmoles) and nicotiny azide (0.25g, 1.69 mmoles, precursor for 3-pyridylisocyanate) in toluene (5.0 mL) was heated at 85 °C under argon for three hours. The reaction mixture was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic phase was washed with saturated sodium chloride solution, dried over magnesium sulfate and evaporated *in vacuo* to obtain a colorless foam (0.52 g). The crude product was chromatographed on silica eluting with ethyl acetate to obtain the title compound as a white solid (0.40 g, 97%); mp 164-166 °C.

Analysis calculated for $C_{18}H_{18}N_4O \cdot 0.23H_2O$:			
	C, 69.63;	H, 5.99;	N, 18.05;
Found:	C, 69.99;	H, 5.86;	N, 17.69

5

Example 810 6-Cyano-2,3-dihydro-3,3-dimethyl-N-(3-pyridinyl)-1H-indole-1-carboxamideA 2,6-Dibromo-3-methylindole

15 A solution of 3-methylindole (13.3 g, 0.1 mole) and N-bromophthalimide (48.2 g, 0.2 mole) in benzene (265 mL) was heated at reflux for one-half hour. The reaction mixture was diluted with ethyl acetate and extracted with 1N sodium hydroxide solution. The organic phase was washed with saturated sodium chloride solution, dried over magnesium sulfate and evaporated *in vacuo* to obtain a black solid (22 g). The crude material was chromatographed on silica eluting with 5% ethyl acetate in hexane to obtain a tan solid (18.5 g) which was crystallized from hexanes to obtain the title compound as an off-white crystalline solid (14.84 g, 51%).

20

B. 6-Bromo-3-methyl-2-oxo-indole

25 A solution of title A compound (12.65 g, 44 mmoles) in dioxane (peroxide free, 250 mL) and 2.5N sulfuric acid (250 mL) was heated at reflux under argon for 24 hours. The reaction mixture was cooled to room temperature, diluted with 1 liter of distilled water and extracted with ethyl acetate. The organic fraction was washed with saturated sodium carbonate solution, saturated sodium chloride solution and dried over magnesium sulfate. The solvent was evaporated *in vacuo* to give the title compound (9.74 g, 98%) as a yellow solid which was used in the next step without further purification.

30

C. 6-Bromo-3-methyl-2-oxo-1H-indole-1-acetamide

35 A solution of title B compound (9.31 g, 41.2 mmoles) in xylene (100 mL) containing acetic anhydride (6.31 g, 1.5 eq.) was heated at reflux for five hours after which time the reaction was incomplete. An additional 0.75 equivalents of acetic anhydride was added and the reaction mixture was heated an additional two hours at reflux. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The crude product solution was washed with distilled water followed by saturated sodium bicarbonate solution and saturated sodium chloride solution. The solvent extract was dried over magnesium sulfate and the solvent was recovered under vacuum to obtain an orange solid (11.4 g). The crude material was chromatographed on silica eluting with hexane/ethyl acetate (3:1) to obtain the title compound (9.18 g, 78%) as an off-white solid; m.p. 102-104°C.

40

Analysis calculated for $C_{11}H_{10}NBrO_2$:			
	C, 49.28;	H, 3.76;	N, 5.22;
Found:	C, 49.23;	H, 3.74;	N, 5.21.

45

D 6-Bromo-3,3-dimethyl-2-oxo-1H-indole-1-acetamide

50

55 To a solution of title C compound (8.98 g, 33.5 mmoles) in dry tetrahydrofuran (90 mL) under argon and cooled to 0°C was added sodium hydride dispersion (60% in mineral oil, 1.05 eq., 1.41 g). The reaction mixture became viscous and was diluted with dry tetrahydrofuran (25 mL). After stirring for 10 minutes, methyl iodide (1.05 eq., 4.75 g) was added dropwise. The reaction mixture was stirred two hours at room temperature, quenched by the addition of saturated ammonium chloride solution and extracted with ethyl acetate. The organic phase was washed with distilled water, saturated sodium chloride solution and dried over magnesium sulfate. The solvent was recovered under vacuum to obtain the title compound (9.67 g, 100%) as an off-white solid. (M + H)⁺ @ 282.

E. 6-Bromo-3,3-dimethyl-2-oxo-indole

A solution of title D compound (9.61 g, 34.1 mmole) in ethanol (80 mL) and 1N sodium hydroxide (20 mL) was stirred at room temperature for one hour. The reaction mixture was partitioned between distilled water and diethyl ether. The organic phase was washed with distilled water, saturated sodium chloride solution and dried over magnesium sulfate. The solvent was recovered under vacuum to obtain the title compound (8.03 g, 98%) as an off-white solid.

F. 6-Bromo-3,3-dimethyl-dihydroindole

To a solution of title E compound (8.0 g, 33.3 mmole) in dry toluene (185 mL) heated to 85 °C was added sodium bis(2-methoxyethoxy)aluminum hydride, (3.4 M in toluene, 14.7 mL, 50 mmole) over the course of 15 minutes. The reaction mixture was heated an additional 15 minutes at 85 °C, cooled to 0 °C and quenched by the addition of 1N sodium hydroxide solution. The phases were separated and the organic phase was washed with 1N sodium hydroxide solution followed by saturated sodium chloride solution. The product solution was dried over magnesium sulfate and evaporated *in vacuo* to obtain a tan solid (7.34 g). The crude material was chromatographed on silica eluting with hexane/ethyl acetate (9:1) to obtain the title compound (5.48 g, 73%) as a pale green solid; m.p. 100-102 °C.

Analysis calculated for C ₁₀ H ₁₂ NBr:					
	C, 53.12;	H, 5.35;	N, 6.19;		
Found:	C, 53.15;	H, 5.32;	N, 6.20	MS:	(M + H) ⁺ @ 226

G. 6-Bromo-3,3-dimethyl-1H-indole-1-acetamide

To a solution of title F compound (5.45 g, 24.1 mmole) in methylene chloride (55 mL) containing triethylamine (2.68 g, 26.5 mmol) cooled to 0 °C was added acetyl chloride dropwise over five minutes. The reaction mixture was stirred 45 minutes at room temperature and partitioned between 1N aqueous hydrochloric acid solution and ethyl acetate. The organic phase was washed with saturated sodium bicarbonate solution, saturated sodium chloride solution, dried over magnesium sulfate and evaporated *in vacuo* to obtain the title compound (6.42 g, 99%) as a pale yellow solid. MS: (M + H)⁺ @ 268.

H. 6-Cyano-3,3-dimethyl-1H-indole-1-acetamide

A solution of title G compound (6.56 g, 24.5 mmole) in N-methylpyrrolidone (70 mL) containing copper(I) cyanide (4.38 g, 48.9 mmole) was heated under argon at 175 °C for three hours. The reaction mixture was cooled to room temperature, diluted with diethyl ether and filtered. The filtrate was washed with distilled water, 1N aqueous hydrochloric acid solution, saturated sodium bicarbonate solution and saturated sodium chloride solution. The crude product solution was dried over magnesium sulfate and evaporated *in vacuo* to obtain the title compound (4.37 g, 83%) as an off-white solid. MS: (M + H)⁺ @ 215.

I. 6-Cyano-3,3-dimethyl-dihydroindole

A solution of title H compound (4.33 g, 20.2 mmole) in a mixture of acetonitrile (120 mL) and 5N aqueous hydrochloric acid (40 mL) was heated at reflux for 1.5 hours. The reaction mixture was cooled to room temperature and carefully neutralized with saturated sodium chloride solution. The oily layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with saturated sodium chloride solution, dried over sodium sulfate and evaporated *in vacuo* to obtain a brown oil. The crude material was purified by chromatography on silica gel eluting with hexane/ethyl acetate (3:2) to give the title compound (3.16 g, 91%) as a yellow solid. MS: (M + H)⁺ @ 173.

J. 6-Cyano-2,3-dihydro-3,3-dimethyl-N-(3-pyridinyl)-1H-indole-1-carboxamide

A solution of title I compound (0.30 g, 1.74 mmoles) and nicotinyl azide (0.32 g, 2.18 mmoles) in toluene (8 mL) was heated at 85 °C for one hour. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate and distilled water. The organic phase was washed with saturated sodium

bicarbonate solution followed by saturated sodium chloride solution. The crude product solution was dried over magnesium sulfate and evaporated under vacuum to obtain a yellow solid. The crude material was purified by chromatography on silica gel eluting with 100% ethyl acetate to afford the title compound (0.41 g) as a white solid; m.p. 220-222 °C.

Analysis calculated for C ₁₇ H ₁₆ N ₄ O:			
	C, 69.85;	H, 5.52;	N, 19.16;
Found:	C, 69.88;	H, 5.55;	N, 19.00

Example 9

1-[(Cyanoimino)(phenylamino)methyl]-2,3-dihydro-3,3-di-methyl-1H-carbonitrile

A 1-[(Cyanoimino)(phenoxy)methyl]-2,3-dihydro-3,3-dimethyl-1H-indole-6-carbonitrile

A solution of title compound 8I (0.65 g, 3.77 mmole), diphenylcyanocarbonimidate (1.08 g, 4.53 mmole) and 1,8-diazabicyclo-[5.4.0]undec-7-ene (0.63 g, 4.15 mmole) in 1,2-dichloroethane (26 mL) was heated at reflux under argon for eight hours. The reaction mixture was diluted with ethyl acetate and washed with 2N hydrochloric acid solution, 1N sodium hydroxide solution and saturated sodium chloride solution. The extract was dried over magnesium sulfate and evaporated *in vacuo* to obtain a yellow solid (1.25 g). The crude material was redissolved in ethyl acetate and filtered through a pad of silica gel to obtain the title compound as a yellow solid (0.99 g, 83%); m.p. 168-170 °C. MS: (M + H)⁺ @ 317.

B 1-[(Cyanoimino)(phenylimino)methyl]-2,3-dihydro-3,3-di-methyl-1H-indole-6-carbonitrile


Trimethylaluminum (2M solution in hexane, 1.74 mmole, 0.87 mL) was added to a solution of aniline (0.16 g, 1.74 mmole) in 1,2-dichloroethane (3.25 mL) under argon. The mixture was stirred at room temperature for 1/2 hour. To the reaction mixture was added a solution of title A compound (0.5 g, 1.58 mmole) in 1,2-dichloroethane (3.25 mL). The reaction mixture was stirred at room temperature for 18 hours, quenched with water, and partitioned between ethyl acetate and 1N sodium hydroxide solution. The organic phase was washed with brine, dried over magnesium sulfate and evaporated *in vacuo* to obtain a pale yellow solid. This was purified by chromatography on silica gel eluting with ethyl acetate/hexane (1:1) and crystallized from isopropanol to obtain the title product (0.22 g, 44%) as an off-white solid; m.p. 224-225 °C.

Analysis calculated for C ₁₉ H ₁₇ N ₅ • 0.30C ₃ H ₈ O:			
	C, 71.69;	H, 5.87;	N, 21.01;
Found:	C, 71.35;	H, 5.40;	N, 20.80.

Claims

1. A compound of the formula

I



or pharmaceutically acceptable salts thereof wherein

A is



or a single bond to complete an indoline nucleus;

X is -O-, -S- or -NCN;

R₁ is aryl, arylalkyl, heterocyclo or (heterocyclo)alkyl;

R₂ is hydrogen, alkyl or arylalkyl;



or R₁ and R₂ taken together form a 5- to 7-membered saturated or unsaturated ring, which may further include an aryl group fused to 2 carbon atoms of such 5- to 7-membered ring;

R₃, R₄, R₇ and R₈ are each independently hydrogen, alkyl or arylalkyl; or R₃ and R₄, or independently R₇ and R₈, taken together with the carbon atoms to which they are attached form a 5- to 7-membered carbocyclic ring, with the proviso that when A is



and R₇ and R₈ are other than hydrogen, then R₃ and R₄ are hydrogen, or when R₇ and R₈ are hydrogen then, R₃ and R₄ are other than hydrogen;

R₅ is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, (cycloalkyl)alkyl, -CN, -NO₂, -COR, -COOR, -CONHR, -CON(R)₂, -CF₃, S-alkyl, -SOalkyl, -SO₂alkyl,



halogen, amino, substituted amino, -O-alkyl, -OCF₃, -OCH₂CF₃, -OCOalkyl, -OCONRalkyl, -NRCOalkyl, NRCOOalkyl or -NRCON(R)₂ wherein R is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl or haloalkyl;

R₆ is hydrogen, alkyl, halo, -OH, -O-alkyl, amino, substituted amino, -O-alkyl, -OCOalkyl, -OCON-

Ralkyl, -NRCOalkyl, -NRCCOalkyl or -NRCON(R)₂; and
n is an integer 1, 2 or 3

2. A compound of claim 1 wherein

5 A is



10

or a single bond,

R₁ is aryl, arylalkyl, heterocyclo or (heterocyclo)alkyl;

R₂ is hydrogen or alkyl;

15 R₃ and R₄ are independently hydrogen or alkyl;

R₅ is an electron withdrawing group;

R₆ is hydrogen, alkyl or O-alkyl;


R₇ and R₈ are independently alkyl; and

X is O or NCN.

20

3. A compound of claim 1 wherein

A is



25

or a single bond,

30 R₁ is phenyl, phenylmethyl, substituted phenyl, substituted phenylmethyl or pyridyl;

R₂ is hydrogen;

R₃ and R₄ are independently hydrogen or methyl;

R₅ is -CN or -NO₂;

R₆ is hydrogen;

35 R₇ and R₈ are independently hydrogen or methyl; and

X is O or NCN.

4. A compound of claim 1 which is 7-cyano-3,4-dihydro-4,4-dimethyl-N-phenyl-1(2H)-quinoline-carboxamide

40

5. A compound of claim 1 which is 7-cyano-3,4-dihydro-4,4-dimethyl-N-(phenylmethyl)-1(2H)-quinoline-carboxamide

6. A compound of claim 1 which is N-(3-chlorophenyl)-7-cyano-3,4-dihydro-4,4-dimethyl-1(2H)-quinoline-carboxamide

45

7. A compound of claim 1 which is 7-cyano-1,2,3,4-tetrahydro-3,3-dimethyl-N-phenyl-1-quinoline-amide.

8. A compound of claim 1 which is 7-cyano-1,2,3,4-tetrahydro-3,3-dimethyl-N-(phenylmethyl)-1-quinoline-amide

50

9. A compound of claim 1 which is 7-cyano-1,2,3,4-tetrahydro-4,4 dimethyl-N-(3-pyridinyl)-1-quinoline-carboxamide

10. A compound of claim 1 which is 7-cyano-1,2,3,4-tetrahydro-3,3-dimethyl-N-(3-pyridinyl)-1-quinolinamide

55

EP 0 610 553 A1

11. A compound of claim 1 which is 6-cyano-2,3-dihydro-3,3-dimethyl-N-(3-pyridinyl)-1H-indole-1-carbox-
amide.
12. A compound of claim 1 which is 1-[(cyanoimino)(phenylamino)-methyl]-2,3-dihydro-3,3-di-methyl-1H-
5 carbonitrile
13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable
carrier therefor
- 10 14. A method of treating an ischemic condition in a mammalian specie comprising administering to a
mammal in need thereof a compound of claim 1

15

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 93 11 7267

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.5)
X	WO-A-89 09217 (BEECHAM GROUP PLC) 5 October 1989 * claims 7,8 * ---	1,2,13	C07D215/48 C07D215/18 C07D401/12 C07D209/08 A61K31/47 A61K31/40
Y	DE-A-28 01 187 (METABIO-JOULLIE) 20 July 1978 * page 18; example 879 * ---	1-14	
X	WO-A-92 14733 (SMITHKLINE BEECHAM P.L.C.) 3 September 1992 * claims 1-9,11-15,17 * ---	1,2,13	
X	WO-A-92 05174 (BEECHAM GROUP PLC) 2 April 1992 * claims 1-8,20-30,57,59 * ---	1,2,13	
X	EP-A-0 377 967 (BEECHAM GROUP PLC) 18 July 1990 * claims 1-9,14,15 * ---	1,2,13	
X	US-A-4 428 881 (GULF OIL CORPORATION) 31 January 1984 * column 1, line 33 - column 1, line 42 * ---	1-3	TECHNICAL FIELDS SEARCHED (Int.Cl.5) C07D A61K
X	EP-A-0 402 716 (BAYER AG) 19 December 1990 * page 50; example 113 * ---	1,2	
X	EP-A-0 287 196 (BEECHAM GROUP PLC) 19 October 1988 * claims 1,2,5,7 * ---	1,2	
X	EP-A-0 247 266 (BEECHAM GROUP PLC) 2 December 1987 * claims 1-9,13,14 * ---	1,2,13	
-/--			
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 6 June 1994	Examiner Herz, C
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 93 11 7267

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.5)
X	CHEMICAL ABSTRACTS, vol. 71, no. 15, 13 October 1969, Columbus, Ohio, US; abstract no. 69992h, A.P. TERENT'EV ET AL. 'Optically active isocyanates. III Synthesis and spectropolarimetric study of optically active N-derivative of urea' page 250 ; * abstract * & Zh. Org. Khim. 5 (6) 1063-70 (1969) ----	1-3	
X	J. MED. CHEM. vol. 33, no. 7 , 1990 pages 1929 - 1932 J. BERMUDEZ ET AL. '5-Hydroxytryptamine (5-HT3) Receptor Antagonists. 2. 1-Indolinecarboxamides' * table I * ----	1,2,13	
Y	J. MED. CHEM. vol. 35, no. 11 , 1992 pages 1954 - 1968 P.D. LEESON ET AL. '4-Amido-2-carboxytetrahydroquinolines. Structure-Activity Relationships for Antagonism at the Glycine Site of the NMDA Receptor' * entire document * ----	1-14	TECHNICAL FIELDS SEARCHED (Int.Cl.5)
Y	J. MED. CHEM. vol. 18, no. 11 , 1975 pages 1077 - 1088 J.L. HUGHES 'Cardiovascular Activity of Aromatic Guanidine Compounds' * entire document * ----- -/--	1-14	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 6 June 1994	Examiner Herz, C
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPF FORM 1501 03/92 (EP/CEN)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 93 11 7267

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
X	FARMACO. ED. SCI. vol. 31, no. 10 , 1976 pages 746 - 754 M. MAZZA ET AL. 'N-Acylindoline ad attività fitotossica' * entire document * -----	1,2	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 6 June 1994	Examiner Herz, C
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 (01.81) (P04-001)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.